Celyad SA
Research Celyad SA (CYAD) on Bullrun: market cap EUR 11.24M, P/E 13.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCYAD
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 11.24M
- P/E13.9
- Financial periodFY2025
- RevenueEUR 21.00K
- Revenue growth-88.7%
- Net incomeEUR 830.00K
- Free cash flow-EUR 6.90M
- Gross margin61.9%
Valuation Snapshot
latest market cap is EUR 11.24M; P/E is 13.9.
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Frequently asked questions
What is Celyad SA's market cap?
Celyad SA's market capitalization is EUR 11.24M.
What is Celyad SA's P/E ratio?
Celyad SA's price-to-earnings (P/E) ratio is 13.9.
What does Celyad SA do?
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies.